KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biolife Solutions (BLFS) Common Equity (2016 - 2025)

Historic Common Equity for Biolife Solutions (BLFS) over the last 16 years, with Q3 2025 value amounting to $353.7 million.

  • Biolife Solutions' Common Equity rose 868.86% to $353.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $353.7 million, marking a year-over-year increase of 868.86%. This contributed to the annual value of $348.9 million for FY2024, which is 333.05% up from last year.
  • Latest data reveals that Biolife Solutions reported Common Equity of $353.7 million as of Q3 2025, which was up 868.86% from $347.2 million recorded in Q2 2025.
  • Biolife Solutions' 5-year Common Equity high stood at $489.3 million for Q3 2021, and its period low was $208.8 million during Q1 2021.
  • Moreover, its 5-year median value for Common Equity was $352.6 million (2025), whereas its average is $370.8 million.
  • In the last 5 years, Biolife Solutions' Common Equity skyrocketed by 32731.31% in 2021 and then crashed by 2477.93% in 2023.
  • Quarter analysis of 5 years shows Biolife Solutions' Common Equity stood at $478.0 million in 2021, then dropped by 23.82% to $364.2 million in 2022, then dropped by 7.28% to $337.7 million in 2023, then increased by 3.33% to $348.9 million in 2024, then rose by 1.38% to $353.7 million in 2025.
  • Its Common Equity was $353.7 million in Q3 2025, compared to $347.2 million in Q2 2025 and $352.6 million in Q1 2025.